Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
Resistance to ALK inhibitors such as lorlatinib often arise due to on-target mutations. Here, the authors show the multi-kinase inhibitor gilteritinib is effective against different mutations that arise during lorlatinib in ALK fusion positive lung cancer to cause resistance.
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/57a69b4d14e444839652b6a01ced7b32 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|